Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I recently moved to Interactive Brokers but my stock hasn't been borrowed at all........
nice work by the Commish but it seems inconsistent to ban menthol cigs and not menthol e-cigs.....
If I were Leo those pictures of colon healing would be 5' by 10'.........maybe even 3D print of super size "walk thru" colons before and after......
I like the speed dating scheduled for after lunch.....hopefully we can get some second dates with a few hot partners....maybe even consumate something :)
actually i don't want the CRO paid if Leo knows the results are not good....
maybe Leo should have offered the CEO all three of our drugs for a 10% royalty on all sales.......if they really are as good as he says IPIX could rake in a few billion a year in royalties......
At what point is CEO held accountable? And how, by who? Not sure I can recall a leader with this volume of overpromise and undelivers
and now for the bad news...... "The commitment fee allocated to the future milestone funding of $2.2 million was fully expensed under Other Expenses, because it is unlikely that the Company will achieve any of the three milestones by September 30, 2018. (see Note 13 to the accompanying financial statements)."
13. Equity Transactions
On June 28, 2018, we entered into a Securities Purchase Agreement with Aspire Capital Fund, LLC, pursuant to which the Company has agreed to sell up to $7.0 million of shares of the Company’s Class A common stock to Aspire Capital, without an underwriter or placement agent.
Pursuant to the Securities Purchase Agreement, and in connection with Aspire Capital’s commitment to purchase additional securities from the Company, on June 28, 2018, the Company agreed to (i) sell to Aspire Capital 5,263,158 shares for a purchase price of $2.0 million and (ii) issue to Aspire Capital 2,736,842 shares of common stock and warrants to purchase 8,000,000 shares of common stock, with such warrants having an exercise price equal to $0.38 per share (the “Commitment Fee”). The Securities Purchase Agreement provides for the sale of up to an additional $5.0 million of the Company’s common stock to Aspire Capital upon the achievement of certain milestones, as follows:
·
on or before September 30, 2018, $1.0 million of the Company’s common stock upon the Company’s announcement of the FDA’s granting of the Company’s request for Breakthrough Therapy Designation for the Company’s Brilacidin compound in the indication of Oral Mucositis;
·
on or before September 30, 2018, $2.0 million of the Company’s common stock upon the Company’s announcement that the Company’s Phase 2b trial of Prurisol on psoriasis has met its primary end point; and
·
on or before September 30, 2018, $2.0 million of the Company’s common stock upon the Company’s announcement that the Company has entered into a licensing arrangement with a pharmaceutical company for any of the Company’s clinical assets that will include an initial payment to the Company of an amount in the double-digits millions of dollars.
At some point don’t the board of directors hold the ceo accountable for meeting/missing objectives, if in fact that’s the case at October 1st?
Comparing Pinto to cigarettes is apples and oranges in terms of causing deaths of its users....
"Reports range from 27 to 180 deaths as a result of rear-impact-related fuel tank fires in the Pinto, but given the volume of more than 2.2 million vehicles sold, the death rate was not substantially different from that of vehicles by Ford's competitors."
"Cigarette smoking is responsible for more than 480,000 deaths per year in the United States, including more than 41,000 deaths resulting from secondhand smoke exposure. This is about one in five deaths annually, or 1,300 deaths every day. On average, smokers die 10 years earlier than nonsmokers."
So the whole pinto fiasco represents 5 hours of the impact that smoking has every day of every year....puts things in perspective doesn't it???
Put another way, annual smoking impact is equivalent to 8,760 pinto like fiascos every year....can you imagine the uproar!!
How many more people have to die before the government takes action?
There are no depths BT won't steep to....time for Mr.Gottlieb to put the petal to the metal....if the auto industry were causing as many ongoing deths as the tobacco industry the US Government would have halted all car sales many years ago. I guess that shows you the power of Big Tobacco.
https://finance.yahoo.com/news/campaign-tobacco-free-kids-investigation-exposes-tobacco-companies-152300598.html
Maybe they haven’t heard of kevetrin?
sure hope this isn't another case of Leo over-promising and under-delivering....
So maybe the company is only just now applying for BTD?
"21) What are the timelines for FDA to respond to a breakthrough therapy designation request?
FDA will respond to breakthrough therapy designation requests within 60 days of receipt of the request."
Just in case you didn’t think Gottlieb was on our side...... “The bottom line is this: Short of perhaps discovering a universal cure for cancer, there’s no single intervention or advance I can achieve on my watch at FDA, or over any reasonable period of time, that’ll have more impact on reducing the death and suffering from cancer than if I’m able to sharply reduce peoples’ use of combustible tobacco -- principally cigarettes.
This has become one of our principal obligations at FDA, and a key part of my efforts as Commissioner.
As part of the comprehensive plan we announced last year, we’re advancing a process to regulate the nicotine levels in cigarettes to render them minimally or non-addictive.”
How much longer will he be commissioner? Get r done!!!!
wow from 40 to 1.20.....everything is relative
They're expecting $300 million in sales this year and have a $6 Billion+ market cap. If we can get B-OM on the market within the next year or two i expect we could double those sales....where would that put IPIX market cap???
I was a little disappointed with her comment at the end when when someone asked why the drop out rate was 30% and she responded something to the effect that the research cigarettes were somewhat awful tasting....I guess if xxii s plan is to license the technology it shouldn’t be an issue
I can see why the FDA originally rejected their application....64% chance of AE....yikes
"treatment-emergent AE rates were 44%, 50%, 47%, 58% and 64% for placebo and 2-, 4-, 8- and 10-mg baricitinib groups, respectively."
I hope you’re right. Would like to see Leo sell or partner B and P for big bucks. Then use some of those funds to prove out K and then sell/partner K for really big bucks five to ten years from now
Interesting that a great deal of GERNs price increase (best performance of any biotech stock of the week) was driven by short covering....Gee I wonder what they're shorting now
Geron: Enjoying a double whammy
Geron was the week's biggest biotech winner, with its share price soaring nearly 71%. There were two interrelated factors that sent the biotech stock into the stratosphere.
First, and most important, Geron provided a pipeline update with its Q4 and full-year 2017 results announced after the market closed on March 16. The company held a conference call to discuss more details on the morning of Monday, March 19. The bottom line from this update was that Geron's lead candidate, imetelstat, appears to be on track, with the company's big partner Johnson & Johnson (NYSE: JNJ) completing a third internal data review of a phase 2 study of the drug in treating myelofibrosis.
This news would have been enough by itself to drive Geron stock higher. But the second reason the stock really took off was that short-sellers have been piling on in recent months. With an improved outlook for imetelstat, these traders were forced to cover their short positions, setting Geron up for a classic short squeeze scenario -- making the stock price go up even more.
3 Biotech Stocks That Skyrocketed This Week: Are They Buys?
https://finance.yahoo.com/news/3-biotech-stocks-skyrocketed-week-133200121.html
Thanks for the article. I especially love this line: “ What matters for companies looking to buy a drug/biotech stock is the current sales performance of the latter's drugs/products, prospects of sales growth, and the quality of the pipeline.”
I don’t see anything there about the price of their stock. But then the FUDsters already know that don’t they.
I really like the 1.1 billion up front cash
I agree using aspire has been a great approach leaving IPIX almost debt free. Don’t forget Leo’s 2 million loan at 10% though......
It seems irresponsible for the FDA to limit nicotine in combustible cigs yet allow it in e-cigarettes. Isn’t adding nicotine the holy grail for any consumable goods company.....make your products addictive
Given recent studies on e-cigarettes it appears big tobacco is flexing its muscles with the FDA.....and replacing one killer with another. ....simply tragic that tobacco companies are allowed to go on killing millions of people with FDA consent.
Instead of big tobacco I think the next big class action lawsuit should be against the FDA.
Reminds me of the late 80s when a driver crashed their car and was injured. They successfully sued the automaker because they “could” have added airbags since the technology was available but they hadn’t in that model. They won millions.
Great sense of value......maybe you'd like to sell your house for $5k?
In CANADA recreational pot will be legalized July 1 2018. Government is finalizing labelling requirements but it looks like amount of THC and CBDs will be required. Seems to me we could license a premium product in THC, not sure if we can tailor CBDs. Although I seem to recall Anandia retained marketing rights in CANADA?
If a licensing deal is close it seems like unnecessary dilution. Maybe Henry sees that deal taking longer to consummate?
I must say I'm a bit surprised dr b signed up for interim initially....or does that decision pre date his arrival?
Yet their MC still over 2billion
I'm all for great news from the conference but let's not get too excited.....when has a conference ever translated into a higher stock price previously
Maybe Henry should give Monsanto a call?
Certainly seems to make the 7million BAT payment a lock within the next 60 days
So any guesses as to the potential "engine" partners discussed during CC? Are they looking to partner with Youtube or someone like that to leverage Clipstream's security software?
IIRC Otezla only had around 13% PASI 75 at 6 weeks so that's the first hurdle with the soon to be released interim P
Allergan paid all that money without a solid phase 2 result like we will have in hand. Guess what Allergan appears to have wasted their money by getting in too early:
www.fiercebiotech.com/biotech/midstage-vitae-drug-flops-phii-leaving-allergan-s-640m-buyout-question
How much more would they've been willing to pay for the proven real deal??
Seems to me BP were on vacation the summer of the polymedix heist....not sure this is a great time of the year to get a BP feeding frenzy going. Probably best to wait until Sept/Oct when they're all back at the controls......then off to the moon :)
Of the "hundreds of other bios" you follow do ANY of their potential drugs activate P53 the "guardian angel gene" in a non-toxic way?
Nice find Slc. Intersting that they ink a billion dollar deal yet their market cap is still only $200mil (granted up 45% on the news).....
Seems to me we ought to be able to charge more for Brilacidin than Kepivance since it will be much more effective...."In people undergoing total body irradiation for a stem cell transplant, 63% receiving Kepivance® developed grade 3 or 4 (severe) oral mucositis compared to 98% of those not receiving Kepivance.®"
http://kepivance.typo3konsult.se/patients/about-kepivance/about-kepivancer/
What would be reasonable 25% more, so $5 Billion/yr becomes $6 Billion/yr sales potential? I really like our odds here.